EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer

Bo-Syong Pan, Cheng-Yu Lin, Gilbert Aaron Lee, Hui-Kuan Lin iD

The Kaohsiung Journal of Medical Sciences · 2025

DOI: 10.1002/kjm2.12933 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2025. Verfasst von Bo-Syong Pan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Neoplasms, Histone-Lysine N-Methyltransferase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SET domain bifurcated histone lysine methyltransferase 1 (SETDB1/ESET), a pivotal H3K9 methyltransferase, has been extensively studied since its discovery over two decades ago. SETDB1 plays critical roles in immune regulation, including B cell maturation, T‐cell activity modulation, and endogenous retrovirus (ERV) silencing. While essential for normal immune cell function, SETDB1 overexpression in cancer cells disrupts immune responses by suppressing tumor immunogenicity and facilitating immune evasion. This is achieved through the repression of anti‐tumor immune cell production, ERV silencing, and interference with the type I interferon pathway leading to inhibiting immune checkpoint blockade (ICB) efficacy. Beyond its immunological implications, SETDB1 overexpression fosters tumor growth and metastasis via transcriptional silencing of tumor suppressor genes through histone regulation and activating oncogenic signaling by non‐histone regulation. These multifaceted roles make SETDB1 an attractive epigenetic target for novel cancer therapies. This review explores SETDB1's dual function in immune regulation and tumor progression, emphasizing its potential in the development of innovative cancer treatments targeting epigenetic dysregulation and oncogenic signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHistone-Lysine N-MethyltransferaseHumansEpigenesis, GeneticAnimalsSignal TransductionGene Expression Regulation, NeoplasticEndogenous RetrovirusesImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

SETDB1cancerendogenous retrovirus silencingimmune checkpoint blockagemethyltransferase

Substanzen

Histone-Lysine N-MethyltransferaseSETDB1 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.

ORCID-Profile: Hui-Kuan Lin

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Pan, B. S., Lin, C. Y., Lee, G. A., & Lin, H. K. (2025). Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12933

Vancouver

Pan BS, Lin CY, Lee GA, Lin HK. Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer. The Kaohsiung Journal of Medical Sciences. 2025. doi:10.1002/kjm2.12933

BibTeX
@article{Pan2025,
  author = {Pan, Bo-Syong and Lin, Cheng-Yu and Lee, Gilbert Aaron and Lin, Hui-Kuan},
  title = {Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer},
  journal = {The Kaohsiung Journal of Medical Sciences},
  year = {2025},
  doi = {10.1002/kjm2.12933}
}
Kostenlos starten →